- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00323323
CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas
A Phase I Study of CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Rationale: The drug combination called CHOP, or Cyclophosphamide (Cytoxan), Doxorubicin (Adriamycin), Vincristine (Oncovin), and Prednisone (Deltasone), has been used against different types of lymphoma for many years. Researchers are investigating what other therapies to combine with the CHOP regimen to improve outcomes for patients with lymphoma. The current study combines CHOP with alemtuzumab, a monoclonal antibody used against leukemia. Monoclonal antibodies are a type of immunotherapy used against some types of cancer. They are produced in a laboratory and designed to target as well as bind with cells that carry specific proteins. Alemtuzumab is designed to target leukemia cells that express a specific protein. The specific protein recognized by alemtuzumab is the CD52 antigen. This antigen, or substance that causes the immune system to create a specific response, is expressed on normal B and T cells, as well as on abnormal T cells characteristic of certain cancers. Alemtuzumab causes the CD52 antigen to bind with B-cell lymphocytes. This study will also assess the theory that alemtuzumab may increase the effectiveness of the chemotherapy agents included in the CHOP regimen.
Treatment: Patients in this study will receive alemtuzumab and CHOP. Alemtuzumab will be given through injections into the skin and CHOP will be administered through intravenous infusions. Patients will receive alemtuzumab alone during the first week of the study. An increasing amount of alemtuzumab will be given during the first week. If patients cannot tolerate the highest amount of alemtuzumab determined as appropriate within one week, they will be removed from the study. Once the highest dose of alemtuzumab has been achieved, patients will then receive both alemtuzumab and CHOP every three weeks. This schedule will be repeated up to eight times. Several tests and exams will be given throughout the study to closely monitor patients. Treatments will be discontinued due to disease growth or unacceptable side effects.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
Ohio
-
Columbus, Ohio, Stati Uniti, 43210
- Ohio State University
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- CD-20 Negative
- Previous treatment permitted: radiation, electron beam radiotherapy, PUVA, corticosteroids, IFN, low dose methotrexate, retinoids, Ontak
- CNS disease permitted
Exclusion Criteria:
- Pregnant or Nursing
- prior Alemtuzumab
- history of active Hep C
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Alemtuzumab/CHOP
For all patients enrolled, the study will begin with a stepped-up schedule of single agent Alemtuzumab given subcutaneously (SQ) on week #1.
Dose escalation will occur during the first week of therapy, starting with 3 mg of Alemtuzumab administered SQ on day 1.
If well tolerated, this will be followed by 10 mg SQ on day 3 and 30 mg (split into 2 injection sites) on day 5. Plasma samples will be obtained for Alemtuzumab pharmacokinetics (PK) during the first week of single agent Alemtuzumab stepped up dosing and subsequently before and after the 5th and the 8th Alemtuzumab/CHOP dose
|
CHOP will be given 60-120 minutes following SQ administration of Alemtuzumab as follows: cyclophosphamide 750 mg/m2 IV on day 1, doxorubicin 50 mg/m2 IV on day 1, vincristine 1.4 mg/m2 (maximum dose = 2 mg) IV on day 1, and prednisone 100 mg PO on days 1-5.
Altri nomi:
Single agent Alemtuzumab given subcutaneously (SQ) on week #1.
Dose escalation will occur during the first week of therapy, starting with 3 mg of Alemtuzumab administered SQ on day 1.
If well tolerated, this will be followed by 10 mg SQ on day 3 and 30 mg (split into 2 injection sites) on day 5.
Altri nomi:
Plasma samples will be obtained for Alemtuzumab pharmacokinetics (PK) during the first week of single agent Alemtuzumab stepped up dosing and subsequently before and after the 5th and the 8th Alemtuzumab/CHOP dose.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
---|---|
Toxicity and safety of concurrent CHOP and Alemtuzumab
Lasso di tempo: up to five years
|
up to five years
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
---|---|
Determine pharmacokinetics of Alemtuzumab
Lasso di tempo: up to five years
|
up to five years
|
Determine immunosuppressive properties of Alemtuzumab + CHOP
Lasso di tempo: up to five years
|
up to five years
|
Determine if Fc Receptor-gamma (FcγR) polymorphism is predictive of response or toxicity with Alemtuzumab treatment.
Lasso di tempo: up to five years
|
up to five years
|
Collaboratori e investigatori
Collaboratori
Investigatori
- Investigatore principale: Pierluigi Porcu, MD, Ohio State University
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie del sistema immunitario
- Neoplasie per tipo istologico
- Neoplasie
- Malattie linfoproliferative
- Malattie linfatiche
- Disturbi immunoproliferativi
- Linfoma
- Effetti fisiologici delle droghe
- Meccanismi molecolari dell'azione farmacologica
- Inibitori enzimatici
- Agenti antinfiammatori
- Agenti antireumatici
- Agenti antineoplastici
- Agenti immunosoppressivi
- Fattori immunologici
- Modulatori della tubulina
- Agenti antimitotici
- Modulatori della mitosi
- Glucocorticoidi
- Ormoni
- Ormoni, sostituti ormonali e antagonisti ormonali
- Agenti antineoplastici, ormonali
- Agenti Antineoplastici, Alchilanti
- Agenti Alchilanti
- Agonisti mieloablativi
- Agenti antineoplastici, fitogenici
- Inibitori della topoisomerasi II
- Inibitori della topoisomerasi
- Agenti antineoplastici, immunologici
- Antibiotici, Antineoplastici
- Ciclofosfamide
- Prednisone
- Doxorubicina
- Vincristina
- Alemtuzumab
Altri numeri di identificazione dello studio
- OSU-0303
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su CHOP
-
Japan Clinical Oncology GroupMinistry of Health, Labour and Welfare, JapanTerminatoLinfoma non-HodgkinGiappone
-
Sherief Abd-ElsalamReclutamento
-
The University of Texas Health Science Center at...RitiratoLinfoma, cellule BStati Uniti
-
Jiangsu HengRui Medicine Co., Ltd.ReclutamentoLinfoma periferico a cellule TCina
-
Nanjing Yoko Biomedical Co., Ltd.ReclutamentoLinfoma diffuso a grandi cellule B, sede non specificataCina
-
King's College Hospital NHS TrustCompletatoLeucemia/linfoma a cellule T dell'adulto associato a HTLV-I (ATLL)Regno Unito
-
Sun Yat-sen UniversityReclutamentoLinperlisib in combinazione con CHOP nel linfoma periferico a cellule T precedentemente non trattatoLinfoma periferico a cellule TCina
-
Children's Hospital of PhiladelphiaNational Institute of Mental Health (NIMH); University of PennsylvaniaIscrizione su invito
-
Haruhiko FukudaMinistry of Health, Labour and Welfare, JapanCompletato
-
Ruijin HospitalThe First Affiliated Hospital of Anhui Medical University; The First Affiliated... e altri collaboratoriReclutamento